This is in agreement with the results of prior studies on OVA-mediated chronic asthma models [13], and further indicates that rosuvastatin treatment leads to a significant decrease of not only Th2 cytokines, but also other mediators, including TNF-α, MMP9, and TGF-β1. The gene discussed is MMP9; the disease is chronic asthma.